Journal of the Canadian Association of Gastroenterology.

• TeilnehmendeR: Canadian Association of Gastroenterology,
• Place / Publishing House: [Oxford] : : Oxford University Press,, [2018]-
• Publication history: Began with Volume 1, Issue 1, suppl1 (February 2018)
• Language: English
• Physical Description: 1 online resource
• Notes: Refereed/Peer-reviewed

Table of Contents

A1 SEMAPHORIN3E (SEMA3E) REGULATES INTESTINAL INFLAMMATION THROUGH THE MODULATION OF DENDRITIC CELLS FUNCTIONS -- A2 LOSS OF MESENCHYMAL BMPS SIGNALING SYNERGIZES WITH TRP53 MUTATION TO INDUCE GASTRIC ONCOGENIC PROGRESSION -- A3 A SERPIN-PRODUCING BIFIDOBACTERIA IMPROVES GLUTEN PATHOLOGY IN MICE -- A4 DIAGNOSIS OF ASTHMA IS ASSOCIATED WITH SUBSEQUENT DEVELOPMENT OF INFLAMMATORY BOWEL DISEASE: A POPULATION-BASED CASE-CONTROL STUDY -- A5 FRUCTOOLIGOSACCHARIDE EXACERBATES INFLAMMATION AND THE LOSS OF MICROBIAL DIVERSITY FOLLOWING ILEOCECAL RESECTION IN A MURINE MODEL OF POST-OPERATIVE CROHN'S DISEASE RECURRENCE -- A6 PREFERENCES FOR CARE FOR ACTIVE SYMPTOMS OF IBD IN A POPULATION BASED SAMPLE -- A7 PI3KP110δ DRIVES INTESTINAL FIBROSIS IN SHIP DEFICIENT MICE Y Lo, J Sauvé, S Menzies, L M Sly -- A8 PROLONGED FASTING ALTERS THE GUT MICROBIOME AND PROTECTS AGAINST SALMONELLA -INDUCED GUT INFLAMMATION -- A9 SHORT-TERM EXPOSURE TO A HIGH SUGAR DIET REDUCES SHORT CHAIN FATTY ACID PRODUCTION AND INCREASES SUSCEPTIBILITY TO COLITIS -- A10 AN ULCERATIVE COLITIS ESCHERICHIA COLI PATHOBIONT COLONIZES THE INTESTINAL MUCOSA OF SUSCEPTIBLE HOSTS AND PROMOTES COLITIS VIA HEMOLYSIN PRODUCTION -- A11 EFFECT OF FECAL MICROBIAL TRANSPLANT ON MICROBIAL AND PHAGE COMPOSITION IN PATIENTS WITH CLOSTRIDIUM DIFFICILE INFECTION -- A12 LOSS OF BMPS SIGNALING IN FOXL1+ SUBEPITHELIAL MYOFIBROBLASTS IMPAIRS SPECIFICATION AND MATURATION OF INTESTINAL EPITHELIAL CELLS -- A13 PROTEOLYTIC BACTERIA PROMOTE INNATE IMMUNE ACTIVATION AND GLUTEN-INDUCED PATHOLOGY IN MICE -- A14 INFLAMMASOME ACTIVATION COORDINATES INTESTINAL MUCOSAL DEFENSE AGAINST THE ENTERIC BACTERIAL PATHOGEN SALMONELLA ENTERICA SEROVAR TYPHIMURIUM -- A15 A PROSPECTIVE, NON-INFERIORITY, MULTI-CENTER, RANDOMIZED TRIAL COMPARING COLONOSCOPY VS ORAL CAPSULE DELIVERED FECAL MICROBIOTA TRANSPLANTATION (FMT) FOR RECURRENT CLOSTRIDIUM DIFFICILE INFECTION (RCDI) -- A16 SUCCESS OF ENHANCED PRIMARY CARE PATHWAYS IN MANAGING ROUTINE GI REFERRALS -- A17 LINEAR GROWTH IMPAIRMENT IN CANADIAN CHILDREN PRESENTING WITH NEW ONSET IBD: A MULTI-CENTRE INCEPTION COHORT STUDY -- A18 IMPROVING COMPLIANCE WITH COLONOSCOPY SURVEILLANCE INTERVAL GUIDELINES -- A19 DEVELOPING A COMPETENCY-BASED PERFORMANCE METRIC OF COLONOSCOPY SKILLS ACQUISITION USING MOTION ANALYSIS - STEP 1: LOW-FIDELITY BENCHTOP MODEL -- A20 PREDICTORS OF PATIENT RELUCTANCE TO USE SPLIT DOSE BOWEL PREPARATION FOR EARLY MORNING COLONOSCOPIES -- A21 RANDOMIZED PROSPECTIVE STUDY: IMPACT OF THE PATIENT EDUCATION WEBSITE ON THE QUALITY OF OUTPATIENT BOWEL PREPARATION FOR COLONOSCOPY -- A22 LIVER TYPE FATTY ACID BINDING PROTEIN (FABP1) LEVELS IMPROVE PERFORMANCE OF PROGNOSTIC MODELS IN ACETAMINOPHEN INDUCED ACUTE LIVER FAILURE -- A23 CIRCULATING PROPIONATE AND SPLANCHNIC VASODILATION IN CIRRHOSIS -- A24 SPECIALIZED MULTIDISCIPLINARY CARE IN CIRRHOSIS IMPROVES MORTALITY AND REDUCES ACUTE CARE UTILIZATION -- A25 HOME EXERCISE THERAPY IS WELL TOLERATED AND IMPROVES EXERCISE CAPACITY IN PATIENTS WITH CHILD PUGH A AND B CIRRHOSIS -- A26 TREATMENT OUTCOMES OF HCV-INFECTED PATIENS IDENTIFIED THROUGH THE COMMUNITY POP-UP CLINIC -- A27 CHARACTERIZATION OF HCV INFECTED PWID IN THE SETTING OF CLINICAL CARE IN CANADA (CAPICA): FINAL RESULTS -- A28 INTRAHEPATIC IL-22 CORRELATES WITH ADVANCED LIVER FIBROSIS AND SENSITIZES HSC TO TGF-β SIGNALING IN A P38-DEPENDENT MANNER -- A29 THE MOLECULAR INTERPLAY BETWEEN CIRCULATING MIR-24, MIR-223, AND PCSK9 IN HEPATITIS C-INFECTED PATIENTS WHO ACHIEVE A TREATMENT-BASED VIRAL CURE -- A30 FIRST YEAR OUTCOMES FROM A PROVINCIALLY FUNDED NON-FIBROSIS RESTRICTED HEPATITIS C TREATMENT PROGRAM IN PRINCE EDWARD ISLAND -- A31 REPROGRAMMING OF EXHAUSTED T CELLS FOLLOWING CURE OF CHRONIC VIRAL INFECTION -- A32 POPULATION-BASED ESTIMATE OF HEPATITIS C VIRUS PREVALENCE IN ONTARIO, CANADA -- A33 NOVEL E2 GLYCOPROTEIN TETRAMER DETECTS HCV-SPECIFIC MEMORY B CELLS -- A34 DARATUMUMAB DOSE DEPENDENT LIVER INJURY -- A35 ACUTE HEPATITIS AS AN ATYPICAL PRESENTATION OF GRAFT-VERSUS-HOST DISEASE IN A PATIENT POST HEMATOPOIETIC STEM CELL TRANSPLANTATION -- A36 INFLIXIMAB INDUCED AUTOIMMUNE HEPATITIS: TWO CASES WITH DIFFERENT OUTCOME -- A37 EFFICACY OF CTA IN DIAGNOSING NON-TRAUMATIC NON-VARICEAL GASTROINTESTINAL BLEEDING PRIOR TO TRANSARTERIAL EMBOLIZATION AFTER ENDOSCOPIC FAILURE IN MANAGING ACUTE GASTROINTESTINAL BLEEDING -- A38 CLINICAL OUTCOMES OF PATIENTS UNDERGOING BALLOON-ASSISTED ENDOSCOPY FOR OBSCURE GASTROINTESTINAL BLEEDING -- A39 A META-ANALYSIS OF COLON CLEANSING PREPARATIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE -- A40 FACTORS AFFECTING MEGAPOLYPECTOMY SUCCESS -- A41 THE PRESENCE OF MELENA PREDICTS A PROXIMAL BLEEDING SITE AMONG PATIENTS WITH OBSCURE GASTROINTESTINAL BLEEDING: RESULTS OF A RETROSPECTIVE COHORT STUDY -- A42 UNDERUSE OF IRON THERAPY UPON DISCHARGE FOR ANEMIC PATIENTS WITH ACUTE GASTROINTESTINAL BLEEDING -- A43 EVALUATING THERAPEUTIC EFFICACY OF TRANS-ARTERIAL EMBOLIZATION IN PATIENTS PRESENTING POST-ENDOSCOPIC FAILURE TO MANAGE ACUTE NON-VARICEAL GASTROINTESTINAL BLEEDING -- A44 MEASURING COLONOSCOPY QUALITY AT THE POPULATION LEVEL IN ONTARIO, CANADA -- A45 IMPACT OF AN ERGONOMIC INTERVENTION ON SIMULATED COLONOSCOPY PERFORMANCE -- A46 SELF-ASSESSMENT ACCURACY OF TECHNICAL AND NON-TECHNICAL SKILLS IN LIVE COLONOSCOPIES BY NOVICE ENDOSCOPISTS -- A47 LONG-TERM CLINICAL OUTCOMES AFTER ENDOSCOPIC TREATMENT FOR SMALL BOWEL VACULAR LESIONS BY DOUBLE BALLOON ENDOSCOPY -- A48 DUODENAL ADENOCARCINOMA: A CASE REPORT -- A49 INNOVATIVE GROUP EDUCATION FOR A COMMON LIVER DISEASE - INCREASING ACCESS TO CARE -- A50 ALBERTA FAMILY PHYSICIAN ELECTRONIC ENDOSOCPY (AFPEE) STUDY RESULTS -- A51 COMPARISON OF THE BOSTON BOWEL PREPARATION SCALE WITH AN AUDITABLE APPLICATION OF THE US MULTI-SOCIETY TASK FORCE GUIDELINES -- A52 PERORAL ENDOSCOPIC MYOTOMY (POEM) FOR TREATING ACHALASIA: A SINGLE CENTER'S RESULTS -- A53 EVALUATING THE DIAGNOSTIC YIELD OF PATIENTS PRESENTING FOR COLONOSCOPY WITH ISOLATED ABDOMINAL PAIN -- A54 IMPROVEMENTS OF GLOBAL RATING SCALE (GRS) CANADA SCORES IN SEVEN ENDOSCOPY UNITS IN THE EDMONTON REGION USING AN INTEGRATED QUALITY IMPROVEMENT PROGRAM -- A55 ASSESSMENT OF THE APPROPRIATE USE OF GASTROINTESTINAL ENDOSCOPY AT A TERTIARY CARE CENTRE -- A56 ENDOSCOPIC PROCEDURE REPORT COMPLETENESS IMPROVES FOLLOWING IMPLEMENTATION OF A DICTATION TEMPLATE AT ST. PAUL'S HOSPITAL -- A57 A NEW STANDARD: AN OPEN-LABEL TRIAL EXAMINING THE EFFECTIVENESS OF INDIVIDUALIZED WEB BASED COLONOSCOPY PREPARATION INSTRUCTION -- A58 PATIENT SATISFACTION WITH ENDOSCOPY UNITS: THE EDMONTON EXPERIENCE -- A59 FACTORS ASSOCIATED WITH ANXIETY ABOUT COLONOSCOPY: THE PREPARATION, THE PROCEDURE, AND THE ANTICIPATED FINDINGS -- A60 IMPROVING PROCESS IN THE EDMONTON PEDIATRIC INFLAMMATORY BOWEL DISEASE CLINIC: AN INFLIXIMAB INFUSION QUALITY IMPROVEMENT PROJECT -- A61 AN ASSESSMENT OF THE EDUCATIONAL EXPERIENCE OF MEDICAL STUDENTS AND RESIDENTS AFTER THEIR GASTROENTEROLOGY AND HEPATOLOGY ROTATIONS -- A62 POST COLONOSCOPY COLORECTAL CANCERS IN ALBERTA.

A PROCESS FOR IDENTIFYING TRUE CASES -- A63 COLONOSCOPY QUALITY IN COLORECTAL CANCER SCREENING: HOW BEST TO CAPTURE THE DATA? -- A64 PERFORMING ERCP AT A CANADIAN ACADEMIC INSTITIUATION: QUALITY PROCEDURES START WITH THE RIGHT INDICATION -- A65 SEVERE CYTOMEGALOVIRUS COLITIS MASQUERADING AS RECURRENT ISCHEMIC COLITIS IN PATIENT WITH END-STAGE RENAL DISEASE -- A66 ABNORMAL THYROID FUNCTION IN CHILDREN WITH CELIAC DISEASE AT DIAGNOSIS AND FOLLOW-UP IN MANITOBA -- A67 PERFORMANCE OF COMPUTED TOMOGRAPHY IN MANITOBA -- A68 IMPACT OF VIDEO CAPSULE ENDOSCOPY ON THE MANAGEMENT OF CHILDREN WITH GASTROINTESTINAL DISORDERS -- A69 PATIENT WAIT TIME RECALL ACURRACY FOR GASTROENTEROLOGY SPECIALTY CONSULTATION IN NOVA SCOTIA -- A70 ACCURACY OF IBD PATIENT WAIT TIME ESTIMATES BY GASTROENTEROLOGISTS IN NOVA SCOTIA -- A71 INFORMED CONSENT AND BOOKING METHOD IN COLONOSCOPY -- A72 BUILDING A SMARTPHONE APPLICATION FOR COLONOSCOPY PREPARATION USING A PATIENT-CENTERED APPROACH -- A73 SURVIVAL PREDICTORS IN PATIENTS UNDERGOING LIVER TRANSPLANT FOR NON-ALCOHOLIC STEATOHEPATITIS: A POPULATION-BASED COHORT STUDY -- A74 THE IMPACT OF SOFOSBUVIR-BASED THERAPY ON RENAL FUNCTION IN HEPATITIS C VIRUS PATIENTS WITH ADVANCED LIVER DISEASE -- A75 TARGETING THE WARBURG EFFECT IN HEPATOCELLULAR CARCINOMA CELLS -- A76 SINGLE OPERATOR PANCREATOSCOPY IN THE EVALUATION OF PANCREATIC NEOPLASMS: A CASE SERIES -- A77 TRACKING WAIT TIMES AND OUTCOMES OF RADIOFREQUENCY ABLATION IN PATIENTS WITH HEPATOCELLULAR CARCINOMA: A QUALITY IMPROVEMENT INITIATIVE -- A78 DIRECT-ACTING ANTIVIRALS ARE NOT ASSOCIATED WITH EARLY TUMOR RECURRENCE AFTER CURATIVE TREATMENTS IN HEPATITIS C-RELATED HEPATOCELLULAR CARCINOMA -- A79 CHARACTERIZATION OF VIPOMA-MEDIATED INTESTINAL EPITHELIAL CELL SECRETION -- A80 ENDOSCOPIC HEALING WITH USTEKINUMAB IN CROHN'S DISEASE: THE UNITI ENDOSCOPY SUB-STUDY -- A81 POOLED SAFETY ANALYSIS FROM THE USTEKINUMAB CROHN'S DISEASE AND PSORIATIC DISEASES PHASE 2 AND 3 TRIALS -- A82 5-ASA & CHEMOPREVENTION IN IBD: A POPULATION-BASED ANALYSIS -- A83 THE MUCOSA-ASSOCIATED-MICROBIOTA IS ASSOCIATED WITH RELAPSE IN CROHN'S DISEASE PATIENTS UNDERGOING ILEOCECAL RESECTION -- A84 HIGH FECAL CALPROTECTIN LEVELS IN ULCERATIVE COLITIS PATIENTS IN CLINICAL REMISSION ARE ASSOCIATED WITH SPECIFIC CLINICAL AND DIETARY INTAKE PARAMETERS -- A85 EFFICACY AND SAFETY OF DOSE ADJUSTMENT AND DELAYED RESPONSE TO USTEKINUMAB IN MODERATE-SEVERE CROHN'S DISEASE: RESULTS FROM THE IM-UNITI MAINTENANCE STUDY -- A86 CHARACTERIZING THE POST-TRANSFER PERIOD AMONGST PATIENTS WITH PEDIATRIC ONSET IBD: THE IMPACT OF ACADEMIC VS. COMMUNITY ADULT CARE ON EMERGENT HEALTH RESOURCE UTILIZATION -- A87 DEVELOPMENT AND VALIDATION OF DIAGNOSTIC CRITERIA FOR IBD WITH AN EMPHASIS ON IBD-UCLASSIFIED IN CHILDREN: A MULTICENTER STUDY FROM THE PEDIATRIC IBD PORTO GROUP OF ESPGHAN -- A88 A PROSPECTIVE STUDY OF MECHANISMS OF INTESTINAL INFLAMMATION AFTER ILEAL RESECTION IN CROHN'S DISEASE: PRELIMINARY ANALYSIS OF PHENOTYPIC PREDICTORS OF ENDOSCOPIC RECURRENCE -- A89 THE IBD SYMPTOM INVENTORY: MEASUREMENT CHARACTERISTICS AND VALIDITY IN A CLINIC SAMPLE --A90 EARLY LIFE INFECTION OF MICE WITH THE TAPEWORM PARASITE HYMENOLEPIS DIMINUTA PROTECTS AGAINST DNBS-INDUCED COLITIS -- A91 NOVEL TRIM22 INTERACTIONS REVEAL POTENTIAL CAUSATIVE MECHANISMS IN VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE (VEOIBD) -- A92 ANTIBIOTICS FOR INDUCTION AND MAINTENANCE OF REMISSION IN CROHN'S DISEASE -- A93 POST-INDUCTION INFLIXIMAB TROUGH LEVELS VARY WIDELY AND AID IN INDIVIDUALIZING INFLIXIMAB MAINTENANCE THERAPY FOR PEDIATRIC IBD -- A94 USE OF LOW-DOSE CTE IN PREDICTING ACTIVE INFLAMMATION IN CROHN'S PATIENTS WITH INTERMEDIATE FECAL CALPROTECTIN LEVELS -- A95 THE EFFICACY OF SURVEILLANCE COLONOSCOPY ON SURVIVAL IN INFLAMMATORY BOWEL DISEASE ASSOCIATED COLORECTAL CANCER: A SYSTEMATIC REVIEW & META-ANALYSIS -- A96 THE TRANSCRIPTION FACTOR HNF4A PLAYS A KEY ROLE IN REGULATING PANETH CELL SPECIFIC WNT3 EXPRESSION AND IS CRUCIAL FOR EPITHELIAL MAINTENANCE. -- A97 IMPACT OF MESENCHYMAL BMP SIGNALING IN ULCERATIVE COLITIS -- A98 VASOACTIVE INTESTINAL PEPTIDE PROMOTES TH17 IMMUNE RESPONSES THEREBY PROTECTING AGAINST CITROBACTER RODENTIUM INDUCED COLITIS -- A99 SYSTEMIC DELIVERY OF AN INHIBITOR OF MITOCHONDRIAL FISSION REDUCES THE SEVRITY OF CHEMICALLY-INDUCED COLITIS IN MICE -- A100 THE UNFINISHED SYMPHONY: GOLIMUMAB IS EFFICIENT AS SALVAGE THERAPY IN PATIENTS WITH REFRACTORY CROHN'S DISEASE -- A101 NO ASSOCIATION WITH RISK OF INFECTION IN IBD WITH HIGH SERUM INFLIXIMAB LEVELS -- A102 THIOPURINE METABOLITE LEVEL MONITORING LEADS TO INDIVIDUALIZED AND OPTIMIZED THIOPURINE THERAPY IN ADULT INFLAMMATORY BOWEL DISEASE (IBD) -- A103 EARLY INITIATION OF ANTI-TNF THERAPY IS COST-SAVING COMPARED TO LATE INITIATION FOR PATIENTS WITH CROHN'S DISEASE -- A104 COST-EFFECTIVENESS OF INFLIXIMAB BIOSIMILAR FOR THE MANAGEMENT OF CROHN'S DISEASE -- A105 AN ONLINE EDUCATIONAL PORTAL IMPROVES CONCERNS OF INFLAMMATORY BOWEL DISEASE PATIENTS REGARDING PREGNANCY AND MEDICATION -- A106 USTEKINUMAB IS EFFECTIVE FOR MAINTAINING CLINICAL RESPONSE IN REFRACTORY MODERATE-TO-SEVERE CROHN'S DISEASE: A MULTICENTRE COHORT STUDY -- A107 POSTOPERATIVE OUTCOMES AMONG USTEKINUMAB TREATED CROHN'S DISEASE PATIENTS: A MULTICENTRE CANADIAN PROVINCIAL EXPERIENCE -- A108 USTEKINUMAB IS EFFECTIVE FOR INDUCING CLINICAL, ENDOSCOPIC, AND RADIOGRAPHIC RESPONSE IN REFRACTORY MODERATE-TO-SEVERE CROHN'S DISEASE: A MULTICENTRE COHORT STUDY -- A109 BIOPSYCHOSOCIAL MODEL OF IBD: CHANGE IN PAIN PHENOTYPES AFFECTS PSYCHOLOGICAL VARIABLES -- A110 THE EFFECT OF SMOKING ON INDUCTION OF REMISSION OR RESPONSE TO ANTI-TUMOR NECROSIS FACTOR THERAPIES IN PATIENTS WITH CROHN'S DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS -- A111 INFLIXIMAB FOR INDUCTION OF REMISSION IN CROHN'S DISEASE -- A112 EARLY USE OF THERAPEUTIC DRUG MONITORING TO INDIVIDUALIZE INFLIXIMAB THERAPY IN PAEDIATRIC IBD: A MULTICENTRE PROSPECTIVE COHORT STUDY -- A113 WHAT IS A FLARE OF IBD? THE MANITOBA LIVING WITH IBD STUDY -- A114 ASSESSMENT OF INFLAMMATORY BURDEN IDENTIFIES CROHN'S DISEASE AND ULCERATIVE COLITIS PATIENT GROUPS WITH DIFFERENT DISEASE-DRIVING PATHWAYS AND THERAPEUTIC RESPONSE TO ANTI-TNF TREATMENT -- A115 ROLE OF GUT SEROTONIN IN ANTIMICROBIAL PEPTIDE PRODUCTION -- A116 ABERRANT IMMUNE RESPONSE AGAINST INVADING BACTERIA INCREASES MORTALITY IN MUC2 MUCIN DEFICIENT MICE IN LPS INDUCED SEPSIS -- A117 IMPLICATION OF LRRK2 IN CROHN'S DISEASE PATHOGENESIS. -- A118 EXPOSURE TO CROHN'S DISEASE-ASSOCIATED ADHERENT-INVASIVE E.COLI (AIEC) AT THE HEIGHT OF INFECTIOUS COLITIS IMPAIRS HOST-MEDIATED CLEARANCE OF AIEC -- A119 THE MICROBIAL METABOLITE SENSOR PREGNANE X RECEPTOR (PXR) RESTRAINS FIBROBLASTS FROM PROMOTING INTESTINAL INFLAMMATION AND FIBROSIS IN MICE -- A120 PREVALENCE OF ANXIETY AND DEPRESSION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE -- A121 DESIGNER PROBIOTICS AS A NOVEL THERAPEUTIC AGAINST INFLAMMATORY BOWEL DISEASE. -- A122 CANADIAN STUDY OF ADHERENCE OUTCOMES IN HUMIRA® (ADALIMUMAB) PATIENTS: THREE-YEAR RESULTS FROM THE COMPANION STUDY IN GASTROENTEROLOGY PATIENTS -- A123 INCREASING TIME ON TREATMENT IS PREDICTIVE OF IMPROVED LONG-TERM RETENTION FOR STABLE REMICADE® (INFLIXIMAB) INFLAMMATORY BOWEL DISEASE PATIENTS IN CANADA -- A124 THE DIAGNOSTIC ACCURACY OF BLOOD AND TISSUE-BASED TESTS FOR CYTOMEGALOVIRUS REACTIVATION IN INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS -- A125 CHARACTERIZATION OF RATES AND PREDICTORS OF VENOUS THROMBOEMBOLISM PROPHYLAXIS IN HOSPITALIZED INFLAMMATORY BOWEL DISEASE PATIENTS AT A TERTIARY CARE CENTRE IN NEW BRUNSWICK, CANADA.

-- A126 REAL WORLD CLINICAL EFFICACY OF LOW DOSE USTEKINUMAB INDUCTION IN CROHN'S PATIENTS REFRACTORY TO ANTI-TNF THERAPY -- A127 CROHN'S DISEASE DIAGNOSIS AFTER PROCTOCOLECTOMY AND ILEAL POUCH-ANAL ANASTOMOSIS FOR ULCERATIVE COLITIS: THERAPEUTIC APPROACH J Hercun, C Richard, R Lahaie, P Poitras -- A128 CROHN'S DISEASE DIAGNOSIS AFTER PROCTOCOLECTOMY AND ILEAL POUCH-ANAL ANASTOMOSIS FOR ULCERATIVE COLITIS: PREDICTIVE FACTORS -- A129 RATES AND CLINICAL PREDICTORS OF URGENT FINDINGS ON ABDOMINOPELVIC COMPUTED TOMOGRAPHY IN EMERGENCY DEPARTMENT PATIENTS WITH INFLAMMATORY BOWEL DISEASE -- A130 TABLEAU DASHBOARD AS A QUALITY IMPROVEMENT AND STRATEGIC DRIVING TOOL IN THE IBD OUTPATIENT SETTING: EARLY EXPERIENCE FROM THE IBD CENTRE OF EXCELLENCE AT THE UNIVERSITY OF ALBERTA HOSPITAL -- A131 ELECTRONIC HEALTH RECORD-BASED SMARTSETS INTEGRATE VARIOUS ASPECTS OF FLARE MANAGEMENT IN OUTPATIENTS WITH INFLAMMATORY BOWEL DISEASE THEREFORE ENSURING CONTINUITY OF CARE -- A132 THREE QUARTERS OF INFLAMMATORY BOWEL DISEASE PATIENTS ON MAINTENANCE INFLIXIMAB THERAPY IN CLINICAL REMISSION SHOW EVIDENCE OF MUCOSAL INFLAMMATION WITH ELEVATED FECAL CALPROTECTIN -- A133 EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB INDUCTION THERAPY IN PATIENTS WITH ULCERATIVE COLITIS: REAL-WORLD EXPERIENCE IN A TERTIARY IBD CENTRE -- A134 ANALYSIS OF POTENTIAL MICROBIAL-METABOLITE SENSORS IN THE BRAIN DURING EXPERIMENTAL COLITIS -- A135 MICROBIOME IN CROHN'S DISEASE PATIENTS: A COMPILATION OF PUBLICLY AVAILABLE DATASETS -- A136 THE ROLE OF KERATIN-19 POSITIVE STEM CELLS IN COLONIC REGENERATION POST COLITIS -- A137 PANCREASTATIN (PTS) EXACERBATES COLONIC INFLAMMATION -- A138 DOES AN EXTRACT OF THE TAPEWORM HYMENOLEPIS DIMINUTA PROMOTE A REGULATORY NEUTROPHIL -- A139 ASYMPTOMATIC IBD IS A COMMON FINDING IN FIT POSITIVE INDIVIDUALS -- A140 ADEQUACY OF PHARMACOLOGIC THROMBOPROPHYLAXIS IN ADULTS HOSPITALIZED FOR ACTIVE INFLAMMATORY BOWEL DISEASE AT THE CIUSSS-CHUS -- A141 DIFFERENT INDUCTION RESPONSE CRITERIA DO NOT INFLUENCE 1 YEAR RESPONSE AND REMISSION RATES OF USTEKINUMAB 90MG Q8W IN PHASE III PROGRAM -- A142 INTER-OBSERVER AGREEMENT AND THE ROLE OF EDUCATIONAL TRAINING ON THE ENDOSCOPIC SCORING OF CROHN'S DISEASE -- A143 FOOD AVOIDANCE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: WHAT, WHEN AND WHO? -- A144 THE EFFICACY OF COLONOSCOPIC BALLOON DILATION IN STRICTURING CROHN'S DISEASE -- A145 "REAL WORLD" SAFETY AND EFFECTIVENESS OF VEDOLIZUMAB FOR ULCERATIVE COLITIS: RETROSPECTIVE STUDY FROM A TERTIARY CARE CANADIAN CENTRE -- A146 ASSESSMENT OF THE USE OF THERAPEUTIC DRUG MONITORING OF INFLIXIMAB DURING MAINTENANCE IN CHILDREN WITH INFLAMMATORY BOWEL DISEASE -- A147 COMBINING INFLIXIMAB TROUGH LEVELS AND FECAL CALPROTECTIN LEVELS WITH CLINICAL DATA HAS THE POTENTIAL TO GUIDE CLINICAL DECISION-MAKING IN IMPROVING OUTCOMES FOR INFLAMMATORY BOWEL DISEASE PATIENTS ON MAINTENANCE INFLIXIMAB -- A148 SMARTPHONE APPS FOR IBD DISEASE MANAGEMENT: A QUANTITATIVE EVALUATION -- A149 DEVELOPING, EVALUATING, AND DISSEMINATING KNOWLEDGE TRANSLATION RESOURCES TO ANSWER PATIENT QUESTIONS ABOUT IBD AND ITS MANAGEMENT -- A150 IBD PATIENTS TRANSITIONING FROM PEDIATRIC TO ADULT CARE LACK THE NECESSARY TRANSITION SKILLS -- A151 MEDICATION INDUCED INTERSTITIAL LUNG DISEASE IN A PATIENT WITH ULCERATIVE COLITIS -- A152 TREATMENT SEQUENCE NETWORK-META ANALYSIS IN CROHN'S DISEASE -- A153 MEASURING QUALITY OF LIFE AND DISEASE ACTIVITY IN PEDIATRIC PATIENTS RECEIVING INDUCTION THERAPY OF EXCLUSIVE ENTERAL NUTRITION OR CORTICOSTEROIDS FOR ACTIVE INFLAMMATORY BOWEL DISEASE -- A154 PROPERDIN DEFICIENCY DOES NOT IMPACT THE MOUSE RESPONSE TO DSS-INDUCED COLITIS DESPITE DIFFERENCES IN COLONIC MICROBIOME -- A155 MOLECULAR LANDSCAPE OF ULCERATIVE COLITIS AND CROHN'S DISEASE IS CONSERVED -- A156 A HELMINTH EXTRACT DOES NOT ALTER THE ABILITY OF HUMAN IL-4 STIMULATED MACROPHAGES TO ENHANCE EPITHELIAL WOUND REPAIR -- A157 INCIDENCE OF VENOUS THROMBOEMBOLIC EVENTS IN PATIENTS WITH ULCERTIVE COLITIS DURING HOSPITALIZED AND POST-DISCHARGE SETTINGS -- A158 THE WAITING GAME: A SYSTEMATIC REVIEW OF ACCESS TO INFLAMMATORY BOWEL DISEASE CARE AND ITS IMPACT ON PATIENT OUTCOMES IN CANADA AND NOVA SCOTIA -- A159 A SURVEY FOR THE USE OF PROBIOTICS, PREBIOTICS AND DIETARY FIBRE SUPPLEMENTS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE -- A160 ESTIMATION OF FIBROSIS PROGRESSION RATES FOR CHRONIC HEPATITIS C: UPDATED META-ANALYSIS AND META-REGRESSION -- A161 ONGOING INCIDENT HEPATITIC C VIRUS INFECTION AMONG PEOPLE WITH A HISTORY OF INJECTING DRUG USE IN AN AUSTRALIAN PRISON SETTING -- A162 SHIFT IN DISPARITIES IN HCV TREATMENT FROM INTERFERON TO DAA ERA: A POPULATION BASED COHORT STUDY -- A163 DIRECT ACTING ANTIVIRAL UPTAKE DISPARITIES IN HIV-HEPATITIS C CO-INFECTED POPULATIONS IN CANADA -- A164 RAPID INTRAHEPATIC AND PERIPHERAL BLOOD HCV RNA DECLINE AND HCV-SPECIFIC IMMUNE RESPONSE INCREASE DURING IFN-FREE DAA THERAPY IN HCV TREATMENT-NAÏVE PATIENTS -- A165 SHORT INJECTION CESSATION EPISODES AS OPPORTUNITIES FOR HEPATITIS C PREVENTION -- A166 SOFOSBUVIR-BASED THERAPY IN THE PRE-LIVER TRANSPLANT SETTING: THE CANADIAN NATIONAL EXPERIENCE -- A167 AN ANALYSIS OF TREATMENT UPTAKE AND EFFICACY USING ALL-ORAL DIRECT-ACTING ANTIVIRAL (DAA) THERAPY IN HCV-INFECTED PEOPLE WHO INJECT DRUGS (PWID) -- A168 USE OF LEDIPASVIR/SOFOSBUVIR (LDV/SOF) WITH OR WITHOUT RIBAVIRIN (RBV) IN GENOTYPE 1 (GT 1) HCV-INFECTED PATIENTS POST LIVER TRANSPLANT (LT): EVALUATION OF SEVERAL REAL-WORLD DATASETS (RWD) -- A169 FLUORESCENT LABELING OF THE HCV HELICASE TO MONITOR NUCLEIC ACID UNWINDING BY FRET -- A170 MACROPHAGE SUBSET PHENOTYPE IS ALTERED IN CHRONIC HCV INFECTION & MAY CONTRIBUTE TO GENERALIZED CD8+T-CELL DYSFUNCTION -- A171 MINIMAL CHANGES IN URINE MARKERS OF TUBULAR DYSFUNCTION IN CHB PATIENTS RECEIVING TAF COMPARED WITH TDF -- A172 C-EDGE CO-STAR: RISK OF REINFECTION FOLLOWING SUCCESSFUL THERAPY WITH ELBASVIR (EBR) AND GRAZOPREVIR (GZR) IN PERSONS WHO INJECT DRUGS (PWID) RECEIVING OPIOD AGONIST THERAPY (OAT) -- A173 EVALUATION OF LIVER FIBROSIS SCORES POST-HCV SVR IN PEOPLE WHO INJECT DRUGS -- A174 A RETROSPECTIVE REVIEW OF CO-PRESCRIBING DIFECT ACTING ANTIVIRALS WITH HMG-COA REDUCTASE INHIBITORS IN HEPATITIS C INFECTED PATIENTS IN A VIRAL HEPATITIS CLINIC -- A175 CAN HCV CORE ANTIGEN REPLACE HCV RNA TESTING IN THE ERA OF DIRECT-ACTING ANTIVIRALS? -- A176 SOFOSBUVIR/VELPATASVIR-BASED REGIMENS ARE ASSOCIATED WITH EXCELLENT EFFICACY AND A SIGNIFICANT IMPROVEMENT OF PATIENTS-REPORTED OUTCOMES ACROSS PATIENT POPULATIONS: FROM NON-CIRRHOTICS TO COMPENSATED CIRRHOTICS TO DECOMPENSATED CIRRHOTICS -- A177 BIRTH COHORT SCREENING FOR HEPATITIS C IN AN OUTPATIENT ENDOSCOPY UNIT: A PILOT STUDY -- A178 ARGONAUTE 2 IS DISPENSABLE FOR EFFICIENT HEPATITIS C VIRUS REPLICATION IN HUH 7.5 CELLS. -- A179 FEATURES OF THE METABOLIC SYNDROME ARE ASSOCIATED WITH LACK OF SERUM ALT NORMALIZATION DURING THERAPY FOR CHRONIC HEPATITIS B -- A180 IMPROVED RENAL LABORATORY PARAMETERS IN CHB PATIENTS TREATED WITH TAF COMPARED WITH TDF -- A181 REAL-LIFE EFFICACY OF ELBASVIR/GRAZOPREVIR (EBV/GZV) FOR THE TREATMENT OF CHRONIC HCV GENOTYPE 1 AND 3 INFECTION -- A182 HEPATOCELLULAR CARCINOMA (HCC) SCREENING PRACTICES IN CHRONIC HEPATITIS B (HBV) AMONG CANADIAN GASTROENTEROLOGISTS AND HEPATOLOGISTS: AN ONLINE SURVEY -- A183 SOFOSBUVIR-BASED ALL-ORAL REGIMENS FOR PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 3 INFECTION: INTEGRATED ANALYSIS OF FIVE CLINICAL STUDIES -- A184 DISSECTING THE ROLE OF THE POLY(C)-BINDING PROTEIN 2 IN THE HEPATITIS C VIRUS LIFE CYCLE -- A185 IMPACT OF HEPATITIS C ERADICATION USING DIRECT ACTING ANTIVIRALS ON CONCURRENT PRIMARY BILIARY CHOLANGITIS AND ASSOCIATED AUTOIMMUNITY.

-- A186 INVESTIGATION OF THE PROTECTIVE ROLE OF MIR-122 AGAINST CELLULAR SENSORS OF RNA AT THE 5' TERMINUS OF HEPATITIS C VIRUS GENOME -- A187 OBSERVATIONAL RETROSPECTIVE ANALYSIS OF PATIENTS IN THE CANADIAN ABBVIECARE (AC) HCV PATIENT SUPPORT PROGRAM -- A188 REAL-LIFE MANAGEMENT OF CHRONIC HEPATITIS C VIRUS INFECTION IN CANADA: DESCRIPTION OF PATIENT PROFILE, PROGNOSTIC FACTORS AND TREATMENT STRATEGIES -- A189 TREATMENT OF CHORNIC HEPATITIS C GENOTYPE 1 IN CANADA: REAL WORLD EXPERIENCE WITH OMBITASVIR/PARITAPREVIR/R AND DASABUVIR WITH OR WITHOUT RIBAVIRIN -- A190 REGRESSION OF LIVER FIBROSIS AFTER SUCCESSFUL ALL ORAL ANTIVIRAL THERAPY IN HCV CIRRHOSIS: A PILOT STUDY EMPLOYING TRANSIENT ELASTOGRAPHY AND CONTROLLED ATTENUATION PARAMETER (CAP) -- A191 NEXT GENERATION SEQUENCING IN THE INVESTIGATION OF HYPERFERRITINEMIA -- A192 PRIMARY SCLEROSING CHOLANGITIS WITH CHOLELITHIASIS IS A DISTINCT PHENOTYPE WITH WORSE SYMPTOMS, DECOMPENSATION-FREE & TRANSPLANT-FREE SURVIVAL -- A193 COGNITIVE DYSFUNCTION IS PRESENT IN HALF OF STABLE OUTPATIENTS WITH CIRRHOSIS AND IS STRONGLY ASSOCIATED WITH THE POTENTIALLY MODIFICABLE FACTORS, DEPRESSION AND LOW MUSCLE STRENGTH -- A194 CAN NOVEL SEROLOGICAL MARKERS BE USED TO BETTER DEFINE PRIMARY BILIARY CHOLANGITIS (PBC)-AUTOIMMUNE HEPATITIS (AIH) OVERLAP SYNDROME -- A195 GLUTAMINE SYNTHETASE IN ENDOTHELIAL CELLS OF THE BLOOD-BRAIN BARRIER: NEW TARGET FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY? -- A196 IDENTIFICATION OF AN IMMUNOSUPPRESSIVE DOMAIN IN HUMAN BETARETROVIRUS -- A197 PREVALENCE OF PRIMARY BILIARY CHOLANGITIS IN CANADA: FIRST NATIONAL STUDY -- A198 PHARMACODYNAMIC EFFECTS OF THE ORAL, NON-STEROIDAL FARNESOID X RECEPTOR AGONIST GS-9674 IN HEALTHY VOLUNTEERS -- A199 SCREENING FOR NONALCOHOLIC FATTY LIVER DISEASE BY TRANSIENT ELASTOGRAPHY WITH CONTROLLED ATTENUATION PARAMETER IN UNSELECTED PATIENTS WITH INFLAMMATORY BOWEL DISEASE -- A200 AN INTEGRATED ANALYSIS OF EFFICACY OF OBETICHOLIC ACID IN CANADIAN PATIENTS -- A201 PREVALENCE OF NONALCOHOLIC FATTY LIVER DISEASE IN A COHORT OF HEALTHY CHILDREN IN ONTARIO -- A202 BIOCHEMICAL PROFILE IN 68 PRIMARY BILIARY CHOLANGITIS (PBC) SUBJECTS HAVING AN INADEQUATE RESPONSE TO URSODEOXYCHOLIC ACID -- A203 ACTIVITY OF MBX-8025, A POTENT AND SELECTIVE PPAR-δ AGONIST, ON BIOCHEMICAL MARKERS OF CHOLESTASIS -- A204 FIBRINOGEN STORAGE DISEASE:A CASE SERIES AND LITERATURE REVIEW -- A205 CONGENITAL ABSENCE OF THE PORTAL VEIN: DOES IT REALLY EXIST? -- A206 PREDICTORS OF HOSPITAL READMISSION FOLLOWING LIVER TRANSPLANTATION: A SINGLE CENTRE EXPERIENCE -- A207 SCLEROSING CHOLANGITIS SECONDARY TO DISSEMINATED VARICELLA ZOSTER VIRUS: A CASE REPORT -- A208 SHP-2 PHOSPHATASE PREVENTS SENESCENCE IN NORMAL AND TUMOR INTESTINAL EPITHELIAL CELLS -- A209 XENOBIOTIC RECEPTOR REGULATION OF CLOSTRIDIUM DIFFICILE-ASSOCIATED TISSUE DAMAGE AND INFLAMMATION -- A210 NEONATAL INFLAMMATORY SKIN AND BOWEL DISEASE CAUSED BY A HOMOZYGOUS EGFR MUTATION: A CASE REPORT AND REVIEW OF THE MEDICAL LITERATURE. -- A211 PROTEOLYTIC CLEAVAGE OF E-CADHERIN BY INFLAMMATORY PROTEASES PRODUCES BIOACTIVE PEPTIDES THAT MODIFY EPITHELIAL FUNCTION -- A212 EXPRESSION AND CHARACTERIZATION OF SOLUBLE PEKIN DUCK PROGRAMMED DEATH-1 -- A213 A SURVEY OF WORKPLACE ACCOMMODATIONS AMONG PERSONS WITH IBD -- A214 AN ANALYSIS OF FIT RESULTS AND NEOPLASTIC FINDINGS FROM THE NEWFOUNDLAND AND LABRADOR COLON CANCER SCREENING PROGRAM -- A215 CHANGING INCIDENCE OF INFLAMMATORY BOWEL DISEASE IN THE PEDIATRIC POPULATION OF BRITISH COLUMBIA -- A216 HEALTH CARE UTILIZATION PATTERNS BASED ON HEALTH ADMINISTRATIVE DATA ARE MODERATELY EFFECTIVE AT PREDICTING DISEASE BEHAVIOUR AT DIAGNOSIS IN ULCERATIVE COLITIS PATIENTS -- A217 HOSPITAL RE-ADMISSION IS ASSOCIATED WITH DECREASED SURIVIVAL IN PATIENTS WITH CIRRHOSIS: A POPULATION-BASED STUDY -- A218 VALIDATION OF A CIRRHOSIS CASE DEFINITION IN CANADIAN ADMINISTRATIVE DATA -- A219 HEPATITIS C IN NOVA SCOTIA PATIENTD WITH HEREDITARY BLEEDING DISORDERS: AUDIT FOR IDENTIFICATION OF PATIENTS FOR POTENTIAL TREATMENT WITH DIRECT ACTING ANTIVIRAL AGENTS -- A220 THE EFFECT OF HOMELESSNESS ON HCV TREATMENT OUTCOMES AMONG PEOPLE WHO INJECT DRUGS -- A221 A RETROSPECTIVE ANALYSIS OF PATIENTS WITH BIOPSY PROVEN NASH IN AN URBAN CENTRE -- A222 INCREASING PREVALENCE OF CIRRHOSIS IN ONTARIO OVER THE LAST 20 YEARS: A POPULATION-BASED STUDY -- A223 MOSAIC: AN INTERNATIONAL MULTICENTRE PROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE THE EPIDEMIOLOGY, HUMANISTIC AND ECONOMIC OUTCOMES OF TREATMENT FOR CHRONIC HEPATITIS C VIRUS (HCV) -- A224 RISK OFGASTRIC CANCER IN PATIENTS WITH GASTRIC INTESTINAL METAPLASIA AT 5-YEAR FOLLOW-UP -- A225 THE UTILITY OF SEPARATE DISTAL AND MID-ESOPHAGEAL BIOPSIES IN THE DIAGNOSIS OF EOSINOPHILIC ESOPHAGITIS (EOE). -- A226 PEDIATRIC COLLAGENOUS GASTRITIS: ENDOSCOPIC & HISTOLOGIC EVOLUTION -- A227 ASSESSING THE BIOEQUIVALENCE OF NON-PRESCRIPTION ESOMEPRAZOLE 20 MG BANDED CAPSULES AND MULTIPLE-UNIT PELLET SYSTEM TABLETS UNDER FASTED AND FED CONDITION -- A228 FIRST REPORT OF ADRENAL CRISIS IN TWO PATIENTS WITH EOSINOPHILIC ESOPHAGITIS -- A229 CLINICAL AND ENDOSCOPIC CHARACTERISTICS OF LYMPHOCYTIC ESOPHAGITIS -- A230 DRESS: AN UNUSUAL CASE OF UPPER GASTROINTESTINAL BLEED -- A231 A RANDOMIZED CLINICAL TRIAL TO DETERMINE THE EFFICACY OF THE BIOVAC DIRECT SUCTION DEVICE DURING UPPER GASTROINTESTINAL BLEEDING: A FEASIBILITY ANALYSIS -- A232 COMBINATION OF EVAC AND BARIATRIC STENTS IN THE MANAGEMENT OF ESOPHAGEAL PERFORATION --A233 ENDOSCOPIC ASSISTED ENUCLEATION OF SMALL GASTRIC SUBEPITHELIAL TUMORS: AN EARLY SINGLE CENTER EXPERIENCE -- A234 A CASE OF OBSCURE GASTROINTESTINAL BLEEDING CAUSED BY BENIGN GASTRIC HYPERPLASTIC POYLPS -- A235 SYSTEMATIC REVIEW AND META-ANALYSIS: COMPARING OF ESTIMATED ENERGY REQUIREMENTS IN CIRRHOTIC PATIENTS USING INDIRECT CALORIMETRY VERSUS PREDICTION EQUATIONS -- A236 METRONIDAZOLE IN THE TREATMENT OF RECURRENT HEPATIC ENCEPHALOPATHY: A CASE SERIES. -- A237 DEVELOPMENT AND EVALUATION OF A WEB-BASED EDUCATIONAL TOOL FOR THE HEPATOPULMONARY SYNDROME --A238 A COMPARATIVE ANALSYS OF FIBROSIS BY TRANSIENT ELASTOGRAPHY AND LIVER BIOPSY IN PATIENTS WITH BIOPSY PROVEN NASH. -- A239 QUALITATIVE EVALUATION OF THE DECISIONS AND EXPERIENCES OF PEOPLE WHO INJECT DRUGS WHO RECEIVED A LIVER DISEASE ASSESSMENT AS PART OF A LIVER HEALTH PROMOTION CAMPAIGN: THE LIVERLIFE STUDY -- A240 AN UNUSUAL PRESENTATION OF HEPATIC ENCEPHALOPATHY: RECURRENT GLOBAL APHASIA -- A241 TIME FROM DIAGNOSTIC ENDOSCOPY TO CURATIVE RESECTION IN PATIENTS WITH COLON CANCER: A POPULATION-BASED STUDY -- A242 THE P2 ISOFORM CLASS OF THE TRANSCRIPTION FACTOR HNF4A PLAYS DNA REPAIR ROLE IN COLORECTAL CANCER -- A243 FUNCTIONAL ROLES OF NCOR1 AND CHD8 PROTEIN INTERACTION IN HUMAN COLORECTAL CANCER CELLS. -- A244 THE FECAL IMMUNOCHEMICAL TEST (FIT): SELECTED ASPECTS REGARDING ITS EFFECTIVENESS FOR COLORECTAL CANCER SCREENING IN QUEBEC CITY. -- A245 THE ROLE OF P53 ON P2Y6R EXPRESSION IN COLORECTAL CANCER -- A246 DUAL DELETION OF EPITHELIAL BMPR1A/PTEN IN MICE IMPAIRS COLONIC MUCOSA IDENTITY. -- A247 RECOGNITION OF LYNCH SYNDROME AMONGST NEWLY DIAGNOSED COLORECTAL CANCER AT ST. PAUL'S HOSPITAL -- A248 INDICATIONS FOR COLONOSCOPY PRE- AND POST-COLON SCREENING PROGRAM AT ST. PAUL'S HOSPITAL -- A249 NEW POTENTIAL ROLE FOR TRANSCRIPTION FACTOR EB IN DNA REPAIR -- A250 UNRESEQUABLE AND METASTATIC PANCREATIC ADENOCARCINOMA IN THE ELDERLY: A 10-YEAR SINGLE-CENTER EXPERIENCE -- A251 TC-325 USE IN MALIGNANT UPPER GASTROINTESTINAL BLEEDS: A MULTICENTRE RETROSPECTIVE STUDY --A252 IMPROVED QUALITY OF LIFE AFTER ENDOSCOPIC THERAPY FOR BARRETT'S ESOPHAGUS: A CANADIAN EXPERIENCE (2010-2016). -- A253 MEASUREMENT OF NATURAL KILLER CELL ACTIVITY (NKA) IN SUBJECTS UNDERGOING COLONOSCOPY:TEST PERFORMANCE OF A NEW BLOOD TEST AT DIFFERENT CUT-OFFS FOR THE DETECTION OF COLORECTAL CANCER (CRC) -- A254 SYNCHRONOUS GASTRIC ADENOCARCINOMA, MUCOSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMA AND GASTROINTESTINAL STROMAL TUMOR.

-- A255 FULL-THICKNESS ENDOSCOPIC COLONIC RESECTION USING AN OVER-THE-SCOPE CLIP: A CASE REPORT -- A256 DETERMINATION OF PROTEOMIC SIGNATURE OF RESPONSE TO NEOADJUVANT RADIO-CHEMOTHERAPY IN COLORECTAL CANCER PATIENTS -- A257 PANCREATOBILIARY CANCER WITH UNUSUAL SITE OF METASTASIS -- A258 HISTOLOGICAL FINDINGS IN PROTOCOL BIOPSIES FOLLOWING PAEDIATRIC LIVER TRANSPLANTATION: LOW INCIDENCE OF ABNORMALITIES WITH TACROLIMUS MONOTHERAPY AT FIVE YEARS -- A259 ELEVATED BIOCHEMICAL LIVER TESTS WITHIN 1-YEAR TRANSPLANT PREDICTS RECURRENT PSC -- A260 OUTCOMES OF LIVER TRANSPLANTATION FOR ACUTE LIVER FAILURE AMONG RECIPIENTS WITH ABO-IDENTICAL VS. ABO-COMPATIBLE VS ABO-INCOMPATIBLE GRAFTS -- A261 DIRECT ACTING ANTIVIRAL THERAPY IS EFFECTIVE IN RECURRENT HEPATITIS C IN BOTH TREATMENT NAIVE AND EXPERIENCED LIVER TRANSPLANT RECIPIENTS: CLINICAL AUDIT OF THE ATLANTIC MULTI-ORGAN TRANSPLANT PROGRAM -- A262 QUALITY OF LIFE IN PRE-ADOLESCENT CHILDREN AFTER PEDIATRIC LIVER TRANSPLANT FOR BILIARY ATRESIA IS SIMILAR IN EUROPE AND CANADA -- A263 IBS-D MICROBIOTA INDUCES GUT-BRAIN DYSFUNCTION BY DISRUPTING INTESTINAL NEURAL AND IMMUNE PATHWAYS -- A264 AUTOPHAGY IS CRITICAL FOR GOBLET CELLS TO MAINTAIN HOMEOSTASIS UNDER HIGH METABOLIC STRESS -- A265 INVOLVEMENT OF LRP6 IN INTESTINAL HOMEOSTASIS AND INFLAMMATION -- A266 AMYLASE TRYPSIN INHIBITORS FROM WHEAT EXACERBATE GLUTEN-INDUCED PATHOLOGY AND ALTER GUT MICROBIOTA IN MICE -- A267 EPIGENETIC ERASERS HDAC1 AND HDAC2 DRIVE INTESTINAL EPITHELIAL CELL BEHAVIOR -- A268 TESTING AND TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION IN HOSPITALIZED INFLAMMATORY BOWEL DISEASE PATIENTS -- A269 IRRITABLE BOWEL SYNDROME PATIENT EXPERIENCE IN CANADA -- A270 EFFECTS OF KETOPROFEN AND ITS HYDROGEN SULFIDE-RELEASING DERIVATIVE ON THE IMMATURE HUMAN INTESTINE -- A271 UNCOVERING GENDER-BASED DIFFERENCES IN UNDIAGNOSED CELIAC DISEASE -- A272 PERFORMANCE OF TISSUE TRANSGLUTAMINASE ANTIBODIES FOR A DIAGNOSIS OF CELIAC DISEASE IS DECREASED IN ADULTS WITH OTHER COMORBIDITIES -- A273 HISTOLOGICAL FINDINGS IN GASTRIC BIOPSIES AT DIAGNOSIS IN AN ADULT CELIAC DISEASE POPULATION -- A274 THE EFFECT OF PRUCALOPRIDE ON SMALL BOWEL TRANSIT TIME FOR INPATIENTS UNDERGOING SMALL BOWEL CAPSULE ENDOSCOPY -- A275 DONOR BODY MASS INDEX (BMI) DOES NOT IMPACT RECIPIENT BMI FOLLOWING FECAL MICROBIOTA TRANSPLANTATION FOR RECURRENT CLOSTRIDIUM DIFFICILE INFECTION -- A276 INVESTIGATING THE ROLE OF TTC7A THROUGH ITS INTERACTION WITH UBR5 TO MAINTAIN CELL SURVIVAL -- A277 CHARACTERISTICS OF PEDIATRIC IBD AT DIAGNOSIS ASSOCIATED WITH SUBSEQUENT USE OF BIOLOGIC THERAPY: A RETROSPECTIVE STUDY -- A278 PLASMA CITRULLINE HAS LIMITED UTILITY TO PREDICT INTESTINAL ADAPTATION IN NEONATAL SHORT BOWEL SYNDROME -- A279 THE EFFECT OF SHAM FEEDING ON SMALL BOWEL TRANSIT TIME IN PATIENTS UNDERGOING CAPSULE ENDOSCOPY -- A280 SPECIALIZED FORMULA USE FOR THE TREATMENT OF COW MILK PROTEIN ALLERGY -- A281 EFFECT OF A GLUTEN FREE DIET ON SYMPTOMS IN IBS PATIENTS STRATIFIED BY ANTIGLIADIN ANTIBODIES -- A282 DOES SERUM ADALIMUMAB LEVEL CORRELATE WITH DISEASE SEVERITY IN PATIENTS WITH CROHN'S DISEASE? -- A283 THE IMPACT INFLAMMATORY BOWEL DISEASE HAS ON BREASTFEEDING PATTERNS -- A284 ARGON PLASMA COAGULATION ALONE OR IN COMBINATION WITH HEMOSPRAY FOR RADIATION PROCTITIS -- A285 PREDICTORS FOR LOCAL RECURRENCE POST-ENDOSCOPIC MUCOSAL RESECTION(EMR) OF COLONIC LESION WITH 3CM IN SIZE OR MORE -- A286 MULTIFACTORIAL ETIOLOGY OF PROTEIN LOSING GASTROENTEROPATHY FOLLOWING FONTAN'S PROCEDURE -- A287 PHYSICAL ACTIVITY AS A MODULATOR OF INTESTINAL MICROBIOTA, IMMUNE RESPONSES, AND SHORT-CHAIN FATTY ACIDS PRODUCTION -- A288 DISTINCT ROLES IN INNATE HOST DEFENSE AND SUSCEPTIBILITY TO COLONIC INJURY IN MUC2 MUCIN DEFICIENT AND SUFFICIENT MICROBIOTA -- A289 THE CROHN'S DISEASE-ASSOCIATED ADHERENT-INVASIVE E. COLI INDUCES MITOCHONDRIAL FRAGMENTATION IN ENTERIC EPITHELIUM THAT IS NOT DEPENDENT ON BACTERIAL SOLUBLE PRODUCTS OR MITOCHONDRIAL REACTIVE OXYGEN SPECIES -- A290 THE ATF6 ARM OF ER STRESS ANTAGONIZES METABOLIC STRESS-INDUCED DECREASES IN EPITHELIAL BARRIER FUNCTION TO COMMENSAL BACTERIA BY PROMOTING XENOPHAGY -- A291 INVESTIGATING THE ROLE OF ANTIBIOTICS AND ADHERENT-INVASIVE E. COLI IN THE PATHOGENESIS OF CROHN'S DISEASE -- A292 NLRP 3 -DEPENDENT PRODUCTION OF ANTIMICROBIAL PEPTIDES DURING CO-INFECTION WITH GIARDIA INTESTINALIS AND E. COLI -- A293 INFLAMMASOME ACTIVATION INCREASES MACROPHAGE MIGRATION THROUGH EPITHELIAL BARRIER DURING CITROBACTER RODENTIUM INFECTION -- A294 ROLE OF MACROPHAGE IN GUT MICROBIOTA-BRAIN SIGNALING -- A295 FUCOSE AVAILABILITY AND ITS UTILIZATION IMPACT IN VIVO ENTERIC PATHOGEN VIRULENCE. -- A296 THE ANTI-COLITIC EFFECT OF INFECTION WITH HYMENOLEPIS DIMINUTA IS NOT OBSERVED IN ANTIBIOTIC TREATED MICE. -- A297 GOBLET CELLS AND INTESTINAL TREFOIL FACTOR PLAY CRITICAL ROLES IN INNATE PROTECTION AGAINST CLOSTRIDIUM DIFFICILT COLITIS AND MEDIATE RECOVERY FOLLOWING CDIF COLITIS. -- A298 A SWITCH FROM MUC2 TRANSCRIPTION TO MUC5AC IS A COMPENSATORY MECHANISM AGAINST THE MUCOLYTIC ACTIVITY OF GIARDIA DUODENALIS -- A299 IDENTIFICATION OF PATHOGENIC BACTERIAL STRAINS IN PAEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASES USING IMMUNOGLOBULIN G AS A MARKER OF VIRULENCE -- A300 DIET-MICROBIOTA INTERACTIONS UNDERLIE SYMPTOMS IN IBSA301 GUT MICROBIOTA FROM A PATIENT WITH GENERALIZED ANXIETY DISORDER INDUCES ANXIETY-LIKE BEHAVIOUR AND ALTERED BRAIN CHEMISTRY IN GNOTOBIOTIC MICE -- A302 LUMINAL SHORT-CHAIN FATTY ACIDS RESTORE MOTILITY IN GERM-FREE MICE -- A303 SIMULTANEOUS PRESSURE WAVES ARE A KEY COMPONENT OF HUMAN COLON MOTOR FUNCTION ASSESSMENT, USING HIGH-RESOLUTION COLONIC MANOMETRY (HRCM) -- A304 FOOD ANTIGEN-STRESS INTERACTION INCREASES PERIPHERAL PAIN SIGNALING IN A MOUSE MODEL OF IBS -- A305 THE PRONOCICEPTIVE EFFECT OF HIGH DOSE OPIOIDS ON MOUSE DRG NEURONS IS MEDIATED BY DELTA OPIOID RECEPTORS -- A306 LACTOBACILLUS RHAMNOSUS JB-1 AMELIORATES COLONIC AGE-RELATED DYSMOTILITY -- A307 EFFECT OF SLOW SYNAPTIC EXCITATION ON MYENTERIC INTRINSIC PRIMARY AFFERENT NEURON BKCA CHANNEL ACTIVITY -- A308 A PRACTICE AUDIT ON THE EFFECTIVENESS OF BIOFEEDBACK THERAPY IN A TERTIARY CARE CENTRE -- A309 ANTIBIOTIC DRIVEN CHANGES IN GUT MOTILITY HIGHLIGHT DIRECT MODULATION OF ENTERIC NERVOUS SYSTEM -- A310 THE INHIBITION OF PTP1B REVERSES IMPAIRED VAGAL AFFERENT SENSITIVITY CAUSED BY DIET-INDUCED OBESITY, REDUCING NITRIC OXIDE AND 2 PORE DOMAIN K+ CONDUCTANCE -- A311 INTERACTION BETWEEN SOCS3 AND NITRIC OXIDE SIGNALLING IN THE EFFECTS OF DIET-INDUCED OBESITY AND LEPTIN ON VAGAL AFFERENT EXCITABILITY -- A312 INVOLVEMENT OF INOS-DERIVED NO IN THE IMPAIRMENT OF MOUSE VAGAL AFFERENT SENSITIVITY IN DIET-INDUCED OBESITY -- A313 MUCOSAL PROTEASES FROM IBS PATIENTS PRODUCE LONG TERM HYPEREXCITABILITY IN NOCICEPTIVE DRG NEURONS BY ACTIVATING NOVEL INTRACELLULAR SIGNALING PATHWAYS -- A314 INTESTINAL EPITHELIAL SPECIFIC DELETION OF HNF4α PREVENTS OBESITY IN HIGH-FAT DIET FED MICE WITHOUT AFFECTING INTESTINAL UPTAKE OF FATTY ACIDS -- A315 FREQUENCY AND PREDICTORS OF FASTING ORDERS IN INPATIENTS WITH ULCERATIVE COLITIS: THE AUDIT OF DIET ORDERS - ULCERATIVE COLITIS (ADORE-UC) STUDY -- A316 ANTIMICROBIAL LOCKS FOR THE PREVENTION OF CATHETER-RELATED BLOOD STREAM INFECTIONS (CRBSI) IN PATIENTS ON PARENTERAL NUTRITION (PN)- A SYSTEMATIC REVIEW -- A317 THE EFFECT OF OMEGA-3 PUFA ON THE DEVELOPING MICROBIOTA AND IMMUNITY OF INFANTS -- A318 OUTCOMES OF PERCUTANEOUS ENDOSCOPIC GASTROSTOMY IN CHILDREN: A 15 YEAR REVIEW -- A319 A NOVEL METHOD FOR PEG-J TUBE INSERTION USING SINGLE BALLOON ENTEROSCOPY AND THE WEDGE TECHNIQUE -- A320 A CURIOUS CASE OF FOUL SMELLING FLATUS -- A321 USING BEDSIDE ULTRASOUND AS A TOOL TO DETECT SARCOPENIA FOR CIRRHOTIC PATIENTS ON TRANSPLANT LIST -- A322 ALBUMIN MODIFIED BODY MASS INDEX FOR THE ASSESSMENT OF CIRRHOTIC PATIENTS UNDERGOING ORTHOTOPIC LIVER TRANSPLANT -- A323 A PERSONALIZED MEDICINE APPROACH TO THE ROLE OF RECTAL INDOMETHACIN IN PREVENTING POST -ERCP PANCREATITIS: A META- ANALYSIS OF AGGREGATE SUBGROUP DATA -- A324 FOUR OR MORE EUS-FNA PASSES FOR PANCREATIC SOLID LESIONS IS ASSOCIATED WITH INCREASED RISK WITHOUT IMPROVING DIAGNOSTIC YIELD: RESULTS FROM THE OTTAWA HOSPITAL EUS RYSE QA INITIATIVE -- A325 RISK EVALUATION OF ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY (ERCP)-RELATED CONTRAST MEDIA (CM) ALLERGIC REACTION AMONG PATIENTS KNOWN FOR ADVERSE REACTION TO IODINE CONTAINING PRODUCT -- A326 HOSPITALIZATIONS FOR ACUTE AND CHRONIC PANCREATITIS IN A.

FRENCH-CANADIAN FOUNDER POPULATION -- A327 OPTIMAL TIMING OF BILIARY DRAINAGE IN SEVERE ASCENDING CHOLANGITIS -- A328 FACTORS PREDICTIVE OF MALIGNANCY IN PATIENTS WITH BILIARY BRUSHINGS OBTAINED BY ERCP -- A329 ROLE OF AMPULLARY BIOPSY IN AUTOIMMUNE PANCREATITIS -- A330 MANAGEMENT OF COMPLEX PANCREATIC FLUID COLLECTIONS USING THE NAGITM COVERED EXPANDABLE METAL STENT -- A331 BOUVERET'S SYNDROME: A RARE CAUSE OF GASTRIC OUTLET OBSTRUCTION -- A332 ERCP COMPETENCY ASSESSMENT TOOL: DEVELOPMENT OF A PROCEDURE-SPECIFIC ASSESSMENT TOOL FOR ERCP. -- A333 THE ROLE OF IMAGING IN DETERMINING PROGNOSIS FOR PRIMARY SCLEROSING CHOLANGITIS: A SYSTEMATIC REVIEW -- A334 A CASE OF PORTAL CAVERNOMA CHOLANGIOPATHY -- A335 BILIARY ATRESIA HOME SCREENING PROGRAM IN BRITISH COLUMBIA: EVALUATION OF FIRST TWO YEARS -- A336 PREVALENCE AND RISK FACTORS FOR TRANSIENT NEONATAL CHOLESTASIS IN A MOTHER AND CHILD TERTIARY UNIVERSITY CENTER -- A337 RESULTS OF PILOT HEPATITIS C SCREENING PROGRAM IN INFANTS BORN TO HIGH RISK MOTHERS -- A338 SEVERE POSTINFANTILE GIANT CELL HEPATITIS IN AN ADOLESCENT MALE RESPONDING TO IMMUNOSUPPRESSIVE THERAPY DESPITE NEGATIVE AUTOIMMUNE MARKERS.